Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer IRVINE, CA – January XX, 2026 () – Mdxhealth SA (NASDAQ: MDXH) (the “Company” or “mdxhealth”), a leading precision diagnostics company, today announced the next major phase of its collaboration with the University of Oxford: the initiation of Genomic Prostate Score (GPS) testing in the l...
CMB.TECH is investing in the Chinese ammonia supply chain and signed an off-take agreement for green ammonia produced by CEEC in the Jilin Province and will own a minority share in privately owned Andefu, one of China's largest ammonia supply chain companies. While CMB.TECH did not disclose any financials on the deal we estimate linked financials are relatively small. CMB.TECH has a sensible but disciplined investment approach towards decarbonisation. Through the offtake agreement and terminal o...
CMB.TECH INVESTS IN CHINESE AMMONIA SUPPLY Antwerp, Dec. 16, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) (“CMBT”, “CMB.TECH” or “the Company”) is pleased to announce the company is investing in the Chinese ammonia supply chain. CMB.TECH has signed an off-take agreement for green ammonia produced by CEEC Hydrogen Energy (“CEEC”) in Jilin Province and will own a minority share in privately owned Jiangsu Andefu Energy Technology Co., Ltd. (“Andefu”) one of China's largest ammonia supply chain companies. Green ammonia produced...
We like the pro-active nature of this deal. CPI completed a capital increase of €55.5m to finance the acquisition of 9 healthcare assets for €142.6m (announced on 3/12). The remaining €87.1m was financed by €47.1m new debt and €40m of existing debt at a low rate (2.9%). This deal will offset the overhang of the lease portfolio expiries for the next 10 years. Hence, CPI addresses a concern that has been weighing on the share price. The rights issue take-up amounted to 62.6%. We believe this is a ...
We remain positive on the Adyen investment case. Its recent CMD underpinned solid growth guidance for the years ahead, and we believe the company's strong foundation, its in-house built end-to-end payment platform, positions it well for further market share gains and long-term growth drivers like agentic commerce. We keep our target price of €1,850 unchanged and reiterate our BUY rating.
Two Directors at Care Property Invest bought/subscribed to 3,429 shares at between 10.500EUR and 11.720EUR. The significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's...
Care property announced the acquisition of 9 care homes (8 in Flanders, 1 in Wallonia) for €142.6m with €8.2m annual rental income (5.75% yield). At the same time, it launches a rights issue of €55.5m at €10.5 per share and funds €87.1m by debt (existing and new). The rights issue will be followed by a private placement of the remaining shares with a number of “backstoppers”, who have irrevocably committed to subscribe to all remaining rights (no rump placement). The seller is Korian Belgium, pa...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.